Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia
The purpose of our study is to provide information on safety and efficacy of ibrutinib as salvage treatment after allo-HSCT for CLL. A total of 56 patients were included, 36 (64%) males; median age at transplantation was 48 years (range: 35-64) and the median number of treatment lines prior to trans...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[2020]
|
| In: |
Bone marrow transplantation
Year: 2019, Jahrgang: 55, Heft: 5, Pages: 884-890 |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/s41409-019-0742-7 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41409-019-0742-7 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41409-019-0742-7 
|
| Verfasserangaben: | Mauricette Michallet, Peter Dreger, Mohamad Sobh, Linda Koster, Jennifer Hoek, Ariane Boumendil, Christof Scheid, Christopher P. Fox, Gerald Wulf, William Krüger, Michel van Gelder, Paolo Corradini, Domenico Russo, Jakob Passweg, Hélène Schoemans, Wolfgang Bethge, Nicolaas Schaap, Jan Cornelissen, Paul Browne, Nadira Durakovic, Lutz Muller, Silvia Montoto, Nicolaus Kroger, Johannes Schetelig, on behalf of the French Cooperative Group for CLL, SFGM-TC, and the EBMT ChronicMalignancy and Lymphoma Working Parties |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1733942033 | ||
| 003 | DE-627 | ||
| 005 | 20241227003548.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200929r20202019xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41409-019-0742-7 |2 doi | |
| 035 | |a (DE-627)1733942033 | ||
| 035 | |a (DE-599)KXP1733942033 | ||
| 035 | |a (OCoLC)1341367921 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Michallet, Mauricette |e VerfasserIn |0 (DE-588)1073541258 |0 (DE-627)829143459 |0 (DE-576)435146513 |4 aut | |
| 245 | 1 | 0 | |a Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia |c Mauricette Michallet, Peter Dreger, Mohamad Sobh, Linda Koster, Jennifer Hoek, Ariane Boumendil, Christof Scheid, Christopher P. Fox, Gerald Wulf, William Krüger, Michel van Gelder, Paolo Corradini, Domenico Russo, Jakob Passweg, Hélène Schoemans, Wolfgang Bethge, Nicolaas Schaap, Jan Cornelissen, Paul Browne, Nadira Durakovic, Lutz Muller, Silvia Montoto, Nicolaus Kroger, Johannes Schetelig, on behalf of the French Cooperative Group for CLL, SFGM-TC, and the EBMT ChronicMalignancy and Lymphoma Working Parties |
| 264 | 1 | |c [2020] | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 7 November 2019 | ||
| 500 | |a Gesehen am 29.09.2020 | ||
| 520 | |a The purpose of our study is to provide information on safety and efficacy of ibrutinib as salvage treatment after allo-HSCT for CLL. A total of 56 patients were included, 36 (64%) males; median age at transplantation was 48 years (range: 35-64) and the median number of treatment lines prior to transplantation was 3 (1-10). The median time between allo-HSCT and Ibrutinib was 30 months (range: 1-140). Overall, 40 (71%) patients responded to Ibrutinib; 23 (41%) PR, and 17 (30%) CR. At time of ibrutinib initiation, ten patients had active chronic GVHD that resolved under Ibrutinib, whilst a single patient developed limited de novo chronic GVHD on Ibrutinib. Fourteen patients discontinued ibrutinib, four because of toxicity and ten because of disease progression. Overall, 14 patients progressed (median PFS = 24 months) among them 10 died. Two-year OS and PFS probabilities were 72% (95% CI: 52-84) and 50% (95% CI: 32-66), respectively. Patients with late relapse after allo-HSCT (≥24 months) had a better PFS after ibrutinib. Our study shows that ibrutinib can be safely administered for CLL relapse after allo-HSCT, with comparable efficacy to non-transplanted patients with high-risk disease. | ||
| 534 | |c 2019 | ||
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 700 | 1 | |a Sobh, Mohamad |e VerfasserIn |4 aut | |
| 700 | 1 | |a Koster, Linda |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hoek, Jennifer |e VerfasserIn |4 aut | |
| 700 | 1 | |a Boumendil, Ariane |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scheid, Christof |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fox, Christopher P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wulf, Gerald |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krüger, William |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gelder, Michel van |e VerfasserIn |4 aut | |
| 700 | 1 | |a Corradini, Paolo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Russo, Domenico |e VerfasserIn |4 aut | |
| 700 | 1 | |a Passweg, Jakob |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schoemans, Hélène |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bethge, Wolfgang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schaap, Nicolaas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cornelissen, Jan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Browne, Paul |e VerfasserIn |4 aut | |
| 700 | 1 | |a Durakovic, Nadira |e VerfasserIn |4 aut | |
| 700 | 1 | |a Muller, Lutz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Montoto, Silvia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kroger, Nicolaus |e VerfasserIn |4 aut | |
| 700 | 1 | |8 1\p |a Schetelig, Johannes |d 1968- |e VerfasserIn |0 (DE-588)120026953 |0 (DE-627)696313138 |0 (DE-576)292002831 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bone marrow transplantation |d London : Springer Nature, 1997 |g 55(2020), 5, Seite 884-890 |h Online-Ressource |w (DE-627)320433366 |w (DE-600)2004030-1 |w (DE-576)091012996 |x 1476-5365 |7 nnas |a Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia |
| 773 | 1 | 8 | |g volume:55 |g year:2020 |g number:5 |g pages:884-890 |g extent:7 |a Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41409-019-0742-7 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41409-019-0742-7 |x Verlag |z lizenzpflichtig |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20200929 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 999 | |a KXP-PPN1733942033 |e 3763874879 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"[2020]","dateIssuedKey":"2020"}],"language":["eng"],"id":{"doi":["10.1038/s41409-019-0742-7"],"eki":["1733942033"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"part":{"volume":"55","text":"55(2020), 5, Seite 884-890","pages":"884-890","extent":"7","year":"2020","issue":"5"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Bone marrow transplantation","title_sort":"Bone marrow transplantation"}],"id":{"eki":["320433366"],"zdb":["2004030-1"],"issn":["1476-5365"]},"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisherPlace":"London ; Basingstoke ; London","dateIssuedDisp":"1997-","dateIssuedKey":"1997","publisher":"Springer Nature ; Macmillan ; Nature Publishing Group"}],"recId":"320433366","pubHistory":["Nachgewiesen 19.1997 -"],"note":["Gesehen am 17.01.25"],"disp":"Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemiaBone marrow transplantation"}],"person":[{"given":"Mauricette","family":"Michallet","display":"Michallet, Mauricette","role":"aut"},{"role":"aut","given":"Peter","display":"Dreger, Peter","family":"Dreger"},{"given":"Mohamad","family":"Sobh","display":"Sobh, Mohamad","role":"aut"},{"role":"aut","given":"Linda","family":"Koster","display":"Koster, Linda"},{"display":"Hoek, Jennifer","family":"Hoek","given":"Jennifer","role":"aut"},{"given":"Ariane","display":"Boumendil, Ariane","family":"Boumendil","role":"aut"},{"display":"Scheid, Christof","family":"Scheid","given":"Christof","role":"aut"},{"given":"Christopher P.","display":"Fox, Christopher P.","family":"Fox","role":"aut"},{"role":"aut","family":"Wulf","display":"Wulf, Gerald","given":"Gerald"},{"role":"aut","family":"Krüger","display":"Krüger, William","given":"William"},{"given":"Michel van","display":"Gelder, Michel van","family":"Gelder","role":"aut"},{"role":"aut","display":"Corradini, Paolo","family":"Corradini","given":"Paolo"},{"role":"aut","given":"Domenico","family":"Russo","display":"Russo, Domenico"},{"role":"aut","display":"Passweg, Jakob","family":"Passweg","given":"Jakob"},{"role":"aut","display":"Schoemans, Hélène","family":"Schoemans","given":"Hélène"},{"role":"aut","display":"Bethge, Wolfgang","family":"Bethge","given":"Wolfgang"},{"role":"aut","given":"Nicolaas","family":"Schaap","display":"Schaap, Nicolaas"},{"family":"Cornelissen","display":"Cornelissen, Jan","given":"Jan","role":"aut"},{"given":"Paul","display":"Browne, Paul","family":"Browne","role":"aut"},{"role":"aut","display":"Durakovic, Nadira","family":"Durakovic","given":"Nadira"},{"role":"aut","display":"Muller, Lutz","family":"Muller","given":"Lutz"},{"display":"Montoto, Silvia","family":"Montoto","given":"Silvia","role":"aut"},{"display":"Kroger, Nicolaus","family":"Kroger","given":"Nicolaus","role":"aut"},{"role":"aut","display":"Schetelig, Johannes","family":"Schetelig","given":"Johannes"}],"title":[{"title":"Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia","title_sort":"Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia"}],"physDesc":[{"extent":"7 S."}],"note":["Published online: 7 November 2019","Gesehen am 29.09.2020"],"recId":"1733942033","name":{"displayForm":["Mauricette Michallet, Peter Dreger, Mohamad Sobh, Linda Koster, Jennifer Hoek, Ariane Boumendil, Christof Scheid, Christopher P. Fox, Gerald Wulf, William Krüger, Michel van Gelder, Paolo Corradini, Domenico Russo, Jakob Passweg, Hélène Schoemans, Wolfgang Bethge, Nicolaas Schaap, Jan Cornelissen, Paul Browne, Nadira Durakovic, Lutz Muller, Silvia Montoto, Nicolaus Kroger, Johannes Schetelig, on behalf of the French Cooperative Group for CLL, SFGM-TC, and the EBMT ChronicMalignancy and Lymphoma Working Parties"]}} | ||
| SRT | |a MICHALLETMIBRUTINIBA2020 | ||